- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug-Makers to add urinary retention as ADR in package insert of Tramadol
![Drug-Makers to add urinary retention as ADR in package insert of Tramadol Drug-Makers to add urinary retention as ADR in package insert of Tramadol](https://medicaldialogues.in/h-upload/2022/05/18/750x450_176557-anti-inflammatory-drugs.webp)
New Delhi: Deliberating the signal review panel (SRP) recommendation received from Pharmacovigilance Programme of India (PvPI), the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has opined that CDSCO may request State Drugs Controllers to direct the manufacturers of Tramadol to include urinary retention as adverse drug reaction in the corresponding package insert of the drug.
This came in line with the recommendation of the signal review panel of National Coordinating Centre(NCC) -Pharmacovigilance Programme of India (PvPI), which was placed before the committee.
Tramadol is a centrally acting synthetic opioid analgesic. It is a centrally acting μ-opioid receptor agonist and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Tramadol binds weakly to κ- and δ-opioid receptors and to the μ-opioid receptor with 6000-fold less affinity than morphine.
Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.
It is reported from the signal review panel of the National Coordinating Centre- Pharmacovigilance Programme of India (PvPI), that Tramadol can lead to urinary retention as adverse drug reaction.
Urinary retention is a condition in which one is unable to empty all the urine from the bladder. Urinary retention is not a disease, but a condition that may be related to other health problems, such as prostate problems in men or a cystocele in women.
At a recent SEC meeting for Analgesic & Rheumatology, the recommendation of the signal review panel, PVPI, IPC, was placed before the committee regarding the adverse reaction related to the Tramadol.
In view of the above, after detailed deliberation, the committee recommended,
"CDSCO should request the State Drug Controllers to direct the manufacturers of the drug to include urinary retention as adverse drug reaction in the corresponding package insert of the drug."
Also Read:Rare case of Serotonin syndrome due to therapeutic dose of Tramadol, bezoar underlying culprit
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.